544. Pharmacokinetic Profile of Ibalizumab From a Phase 3 Trial

BACKGROUND: Ibalizumab (IBA) is a long-acting humanized monoclonal antibody that binds domain 2 of the CD4 receptor and blocks HIV-1 infection of host cells. TMB-301 was a 24-week, Phase 3 clinical trial conducted in 40 heavily treatment-experienced patients with multidrug-resistant (MDR) HIV-1 inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Princy N, Weinheimer, Steven, Cohen, Zvi, Marsolais, Christian, Kuo, Kuei-Ling, Lewis, Stanley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255274/
http://dx.doi.org/10.1093/ofid/ofy210.552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255274/
http://dx.doi.org/10.1093/ofid/ofy210.552

Ejemplares similares